How is belantamab mafodotin currently used in clinical practice for MM?
The Multiple Myeloma Hub spoke with Fredrik Schjesvold, Oslo University Hospital, Oslo, NO. We asked how belantamab mafodotin is currently used in clinical practice for multiple myeloma (MM).
In this interview, Schjesvold discusses the current use of belantamab mafodotin-based combinations in early relapsed/refractory MM, including their positioning alongside other available treatment options, such as B-cell maturation antigen (BCMA)-directed therapies. Schjesvold also outlines how toxicities, patient characteristics, and individual preferences influence treatment selection in routine…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.